Zhao Heping, Feng Anping, Luo Dan, Yuan Tanwei, Lin Yi-Fan, Ling Xuemei, Zhong Huolin, Li Junbin, Li Linghua, Zou Huachun
Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China.
BMC Infect Dis. 2024 Jan 29;24(1):138. doi: 10.1186/s12879-024-09021-9.
Among people living with HIV (PLHIV) on antiretroviral therapy (ART), the mortality of immunological non-responders (INRs) is higher than that of immunological responders (IRs). However, factors associated with immunological non-response following ART are not well documented.
We obtained data for HIV patients from the National Free Antiretroviral Treatment Program database in China. Patients were grouped into IRs (CD4 cell count ≥ 350 cells/μl after 24 months' treatment), immunological incomplete responders (ICRs) (200-350 cells/μl) and INRs (< 200 cells/μl). Multivariable logistic regression was used to assess factors associated with immunological non-response.
A total of 3900 PLHIV were included, among whom 2309 (59.2%) were IRs, 1206 (30.9%) ICRs and 385 (9.9%) INRs. In multivariable analysis, immunological non-response was associated with being male (2.07, 1.39-3.09), older age [40-49 years (vs. 18-29 years): 2.05, 1.29-3.25; 50-59 years: 4.04, 2.33-7.00; ≥ 60 years: 5.51, 2.84-10.67], HBV co-infection (1.63, 1.14-2.34), HCV co-infection (2.01, 1.01-4.02), lower CD4 + T cell count [50-200 cells/μl (vs. 200-350 cells/μl): 40.20, 16.83-96.01; < 50 cells/μl: 215.67, 85.62-543.26] and lower CD4/CD8 ratio (2.93, 1.98-4.34) at baseline. Compared with patients treated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) based regimens, those receiving protease inhibitors (PIs) based regimens were less likely to be INRs (0.47, 0.26-0.82).
We found a sizable immunological non-response rate among HIV-infected patients. Being male, older age, coinfection with HBV and HCV, lower CD4 + T cell count and lower CD4/CD8 ratio are risk factors of immunological non-response, whereas PIs-based regimens is a protective factor.
在接受抗逆转录病毒治疗(ART)的艾滋病毒感染者(PLHIV)中,免疫无应答者(INR)的死亡率高于免疫应答者(IR)。然而,ART后与免疫无应答相关的因素尚无充分的文献记载。
我们从中国国家免费抗逆转录病毒治疗项目数据库中获取了艾滋病毒患者的数据。患者被分为IR组(治疗24个月后CD4细胞计数≥350个/μl)、免疫不完全应答者(ICR)组(200 - 350个/μl)和INR组(<200个/μl)。采用多变量逻辑回归评估与免疫无应答相关的因素。
共纳入3900例PLHIV,其中2309例(59.2%)为IR,1206例(30.9%)为ICR,385例(9.9%)为INR。在多变量分析中,免疫无应答与男性(2.07,1.39 - 3.09)、年龄较大[40 - 49岁(对比18 - 29岁):2.05,1.29 - 3.25;50 - 59岁:4.04,2.33 - 7.00;≥60岁:5.51,2.84 - 10.67]、合并HBV感染(1.63,1.14 - 2.34)、合并HCV感染(2.01,1.01 - 4.02)、基线时较低的CD4 + T细胞计数[50 - 200个/μl(对比200 - 350个/μl):40.20,16.83 - 96.01;<50个/μl:215.67,85.62 - 543.26]以及较低的CD4/CD8比值(2.93,1.98 - 4.34)相关。与接受基于非核苷类逆转录酶抑制剂(NNRTI)方案治疗的患者相比,接受基于蛋白酶抑制剂(PI)方案治疗的患者更不易成为INR(0.47,0.26 - 0.82)。
我们发现艾滋病毒感染患者中存在相当比例的免疫无应答率。男性、年龄较大、合并HBV和HCV感染、较低的CD4 + T细胞计数以及较低的CD4/CD8比值是免疫无应答的危险因素,而基于PI的方案是一个保护因素。